vs
BIOMERICA INC（BMRA）与MYRIAD GENETICS INC（MYGN）财务数据对比。点击上方公司名可切换其他公司
MYRIAD GENETICS INC的季度营收约是BIOMERICA INC的173.4倍（$209.8M vs $1.2M）。MYRIAD GENETICS INC同比增速更快（-0.4% vs -26.0%）。过去两年BIOMERICA INC的营收复合增速更高（9.1% vs 1.9%）
Biomerica Inc.是一家全球性医疗技术企业，研发、生产及销售诊断检测试剂盒与相关医疗产品，产品线覆盖胃肠疾病、传染病、食物不耐受检测及即时检测解决方案，服务全球多地的临床实验室、医疗机构及零售医疗客户。
麦利亚德基因公司是总部位于美国犹他州盐湖城的美国基因检测与精准医疗企业。公司拥有多项自主专利技术，帮助医生与患者了解人类疾病的遗传基础，以及基因在疾病发生、发展和治疗中发挥的作用，相关成果可用于开发评估患病风险、指导疾病诊疗的新产品。
BMRA vs MYGN — 直观对比
营收规模更大
MYGN
是对方的173.4倍
$1.2M
营收增速更快
MYGN
高出25.7%
-26.0%
两年增速更快
BMRA
近两年复合增速
1.9%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.2M | $209.8M |
| 净利润 | $-1.3M | — |
| 毛利率 | 4.2% | 70.0% |
| 营业利润率 | -113.5% | -2.7% |
| 净利率 | -109.1% | — |
| 营收同比 | -26.0% | -0.4% |
| 净利润同比 | -38.9% | — |
| 每股收益（稀释后） | $-0.45 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRAMYGN
| Q4 25 | $1.2M | $209.8M | ||
| Q3 25 | $1.4M | $205.7M | ||
| Q2 25 | $749.0K | $213.1M | ||
| Q1 25 | $1.1M | $195.9M | ||
| Q4 24 | $1.6M | $210.6M | ||
| Q3 24 | $1.8M | $213.3M | ||
| Q2 24 | $1.1M | $211.5M | ||
| Q1 24 | $1.0M | $202.2M |
净利润BMRAMYGN
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $2.0K | $-27.4M | ||
| Q2 25 | $-1.5M | $-330.5M | ||
| Q1 25 | $-1.2M | $-100.0K | ||
| Q4 24 | $-950.0K | — | ||
| Q3 24 | $-1.3M | $-22.1M | ||
| Q2 24 | $-1.4M | $-36.7M | ||
| Q1 24 | $-1.9M | $-26.0M |
毛利率BMRAMYGN
| Q4 25 | 4.2% | 70.0% | ||
| Q3 25 | 30.7% | 69.9% | ||
| Q2 25 | -33.0% | 71.2% | ||
| Q1 25 | 1.7% | 68.5% | ||
| Q4 24 | 26.7% | 71.7% | ||
| Q3 24 | 16.0% | 70.2% | ||
| Q2 24 | 2.1% | 69.6% | ||
| Q1 24 | -14.7% | 68.1% |
营业利润率BMRAMYGN
| Q4 25 | -113.5% | -2.7% | ||
| Q3 25 | -81.0% | -11.3% | ||
| Q2 25 | -209.1% | -154.5% | ||
| Q1 25 | -108.1% | -14.8% | ||
| Q4 24 | -60.7% | -18.6% | ||
| Q3 24 | -75.7% | -9.4% | ||
| Q2 24 | -136.6% | -17.3% | ||
| Q1 24 | -196.7% | -13.8% |
净利率BMRAMYGN
| Q4 25 | -109.1% | — | ||
| Q3 25 | 0.1% | -13.3% | ||
| Q2 25 | -206.1% | -155.1% | ||
| Q1 25 | -103.9% | -0.1% | ||
| Q4 24 | -58.1% | — | ||
| Q3 24 | -72.8% | -10.4% | ||
| Q2 24 | -127.1% | -17.4% | ||
| Q1 24 | -188.6% | -12.9% |
每股收益（稀释后）BMRAMYGN
| Q4 25 | $-0.45 | $-0.09 | ||
| Q3 25 | $0.00 | $-0.29 | ||
| Q2 25 | $-0.99 | $-3.57 | ||
| Q1 25 | $-0.48 | $0.00 | ||
| Q4 24 | $-0.06 | $-0.47 | ||
| Q3 24 | $-0.63 | $-0.24 | ||
| Q2 24 | $-2.57 | $-0.41 | ||
| Q1 24 | $-0.11 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $149.6M |
| 总债务越低越好 | — | $119.9M |
| 股东权益账面价值 | $4.4M | $368.0M |
| 总资产 | $6.0M | $706.6M |
| 负债/权益比越低杠杆越低 | — | 0.33× |
8季度趋势，按日历期对齐
现金及短期投资BMRAMYGN
| Q4 25 | $2.5M | $149.6M | ||
| Q3 25 | $3.1M | $145.4M | ||
| Q2 25 | $3.1M | $74.4M | ||
| Q1 25 | $3.1M | $91.8M | ||
| Q4 24 | $2.4M | $102.4M | ||
| Q3 24 | $2.8M | $99.9M | ||
| Q2 24 | $4.2M | $97.3M | ||
| Q1 24 | $5.3M | $104.3M |
总债务BMRAMYGN
| Q4 25 | — | $119.9M | ||
| Q3 25 | — | $119.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BMRAMYGN
| Q4 25 | $4.4M | $368.0M | ||
| Q3 25 | $5.2M | $372.8M | ||
| Q2 25 | $4.1M | $388.1M | ||
| Q1 25 | $5.5M | $704.9M | ||
| Q4 24 | $5.1M | $701.1M | ||
| Q3 24 | $5.3M | $731.7M | ||
| Q2 24 | $6.6M | $740.5M | ||
| Q1 24 | $7.8M | $760.0M |
总资产BMRAMYGN
| Q4 25 | $6.0M | $706.6M | ||
| Q3 25 | $6.9M | $728.1M | ||
| Q2 25 | $5.9M | $677.3M | ||
| Q1 25 | $7.4M | $1.0B | ||
| Q4 24 | $7.3M | $1.0B | ||
| Q3 24 | $7.9M | $1.1B | ||
| Q2 24 | $9.3M | $1.1B | ||
| Q1 24 | $10.3M | $1.1B |
负债/权益比BMRAMYGN
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-991.0K | $10.6M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BMRAMYGN
| Q4 25 | $-991.0K | $10.6M | ||
| Q3 25 | $-268.0K | $21.1M | ||
| Q2 25 | $-661.0K | $-13.6M | ||
| Q1 25 | $-1.0M | $-16.3M | ||
| Q4 24 | $-791.0K | $6.6M | ||
| Q3 24 | $-1.3M | $700.0K | ||
| Q2 24 | $-1.0M | $2.6M | ||
| Q1 24 | $-1.8M | $-18.6M |
自由现金流BMRAMYGN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.1M | — | ||
| Q1 24 | — | — |
自由现金流率BMRAMYGN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -95.5% | — | ||
| Q1 24 | — | — |
资本支出强度BMRAMYGN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 0.0% | — |
现金转化率BMRAMYGN
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
